Ab­b­Vie puts up $40M to li­cense a treat­ment from HotSpot Ther­a­peu­tics

HotSpot Ther­a­peu­tics has man­aged to gain some steam fi­nan­cial­ly in the past few years, as the com­pa­ny wran­gled sev­er­al mul­ti-mil­lion dol­lar rais­es. But its lat­est deal not on­ly puts more cash in­to its pock­ets, it al­so con­nects with a ma­jor name in phar­ma.

On Tues­day, Ab­b­Vie and HotSpot an­nounced they have en­tered an “ex­clu­sive” glob­al col­lab­o­ra­tion, with the op­tion to li­cense HotSpot’s IRF5 pro­gram, which is de­signed to treat au­toim­mune dis­eases. The deal will see Ab­b­Vie hand HotSpot $40 mil­lion up­front, with the biotech el­i­gi­ble to re­ceive $295 mil­lion in “op­tion fees” and R&D mile­stones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER